NCT03809351 · Phase 1 · RECRUITING
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
This study uses a brain scan, a PET scan with a tracer called AV-1451, to look at where tau builds up in the brain. Tau is a protein tied to Alzheimer's. Researchers will compare the scans with race, vascular risk factors like blood pressure, and thinking ability. It is an early Phase 1 imaging study, not a treatment test.
You may qualify if
- Enrollment in the UAB-ADC study under a separate IRB-approved research protocol.
- Enrollment in the UAB-ADC amyloid-PET substudy under a separate IRB-approved research protocol. The amyloid-PET study does not have to have been completed prior to enrollment and participation in this tau-PET study.
- Negative urine or serum hCG test within 2 days of [F-18]AV-1451 administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
You're excluded if
- Meets any exclusion criteria for the UAB-ADC study.
- Inability or contraindication for undergoing MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of dementia
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-12